Press Release Description

Global Artificial Intelligence (AI) in Cancer Diagnostic Market to Grow at a CAGR of 40.1% through 2026

Cancer is a fatal disease. Therefore, various innovations, researches, and investments have always been on the higher side in this case. In 2020 alone, the number of cases increased to 13.9 million and deaths to 10 million globally, claims Union for International Cancer Control. 

According to a new study by MarkNtel Advisors, the Global Artificial Intelligence (AI) in Cancer Diagnostic Market is expected to grow at a CAGR of 40.1% during 2021-26. The primary factors driving the market growth are the mounting prevalence of cancer and the rising demand for advanced technologies for the identification & screening of cancer across the world.

Additionally, spurring acceptance of AI in the healthcare industry fuels the adoption of AI in cancer diagnostics. The proven benefits of AI in cancer diagnostics shall also boost the market growth across the globe, further states the research report, “Global Artificial Intelligence (AI) in Cancer Diagnostic Market Analysis, 2021.” 

Screening and Detection Acquired the Largest Share of Global Artificial Intelligence (AI) in Cancer Diagnostic Market

Based on the Application, the market segments into Screening & Diagnosis, Tumor Identification, Treatment, and Surveillance. Of these, Screening & Diagnosis segment held the highest share in the Global Artificial Intelligence (AI) in Cancer Diagnostic Market in the previous few years.

Integration of AI in cancer diagnosis has shown remarkable accuracy in scanning abnormalities that are invisible by the naked eye, which, in turn, reduces the risk of missing any detail and helps in planning appropriate patient-centric treatment. Additionally, the usage of AI in the treatment of cancer has been documenting positive results with the help of a large amount of data acquired from the different treatments of an individual. Hence, the adoption of AI is dramatically increasing for cancer diagnosis across the globe.

“Global Artificial Intelligence (AI) in Cancer Diagnostic Market Analysis, 2021” highlights insights on the market potential & opportunities, along with business strategies to enhance the overall market growth. The report offers an overview of leading market players and their recent developments. Moreover, the report provides incredible market opportunities & emerging trends to help stakeholders make appropriate decisions before investing. 

Global Artificial Intelligence (AI) in Cancer Diagnostic Market

North America is the Dominating Region in the Global Artificial Intelligence (AI) in Cancer Diagnostic Market

The AI in Cancer Diagnostics Market witnessed significant growth across North America in the previous few years, owing to the rising adoption of AI technology across the healthcare industry. Additionally, an increasing number of startups operating the cancer diagnostics market in the region shall also boost the market growth. According to Canadian Cancer Statistics, 43% of women and 45% of men in Canada would have cancer in their lifetime. It implies a surging demand for integrating AI in cancer diagnostics, thereby fueling the overall market growth in the region.

Key Market Competitors

According to MarkNtel Advisors, the leading industry players in the Global Artificial Intelligence (AI) in Cancer Diagnostic Market are Pfizer, Therapixel, Sophia Genetics, Freenome, Tempus, Janssen Pharmaceutica, Path AI, Google Deep Mind, IBM, Microsoft, Cerner Corporation, RaySearch Laboratories, Flatiron, Oncology Analytics, Inc, Oncora Medical, and Others.

Key Questions Answered in the Study

  1. What are the current and future trends in the Global Artificial Intelligence (AI) in Cancer Diagnostic market? 
  2. How has the industry been evolving in terms of geography and services adoption?
  3. How has the competition been shaping across the globe, followed by their comparative factorial indexing?
  4. What are the key growth drivers and challenges for the Global Artificial Intelligence (AI) in Cancer Diagnostic market?
  5. What are the customer orientation, purchase behavior, and expectations from Artificial Intelligence (AI) in Cancer Diagnostic providers across the globe?

Market Segmentation:

  1. By Application (Screening & Diagnosis, Tumor Identification, Treatment, Surveillance)
  2. By Cancer Type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Other (Pancreatic, Skin, Blood, etc.))
  3. By End User (Hospitals, Medical Research Institutes, Diagnostics Centers, Contract Research Organizations)
  4. By Geographic Region (North America, Latin America, Europe, Middle East & Africa, Asia Pacific)
  5. By Countries (US, Canada, Mexico, Brazil, Germany, France, Spain, Italy, Russia, The UK, South Africa, Saudi Arabia, China, India, Japan, Australia, South Korea)
  6. By Competitors (Pfizer, Therapixel, Sophia Genetics, Freenome, Tempus, Janssen Pharmaceutica, Path AI, Google Deep Mind, IBM, Microsoft, Cerner Corporation, RaySearch Laboratories, Flatiron, Oncology Analytics, Inc, Oncora Medical, Others)

Place an order
Only market data will be provided in the excel spreadsheet.

USD 3,700

The report will be delivered in PDF format without printing rights. It is advised for a single user.

USD 4,850

The report will be delivered in PDF format with printing rights. It is advised for up to five users.

USD 6,000

The report will be delivered in PDF format with printing rights and excel sheet. It is advised for companies where multiple users would like to access the report from multiple locations

USD 7,500

Need Assistance?

WRITE AN EMAIL

[email protected]
100% Safe & Secure

Strongest encryption on the website to make your purchase safe and secure